Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Direxion Daily S&P 500 Bull 3X Shares (SPXL) vs TransMedics Group Inc (TMDX) Price & Performance

Direxion Daily S&P 500 Bull 3X SharesTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Direxion Daily S&P 500 Bull 3X Shares vs TransMedics Group Inc — how do they compare? Direxion Daily S&P 500 Bull 3X Shares trades at $270.4, while TransMedics Group Inc trades at $73.5 (market cap $2.54B). The key difference: Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

SPXLTMDX
Sector
Leveraged / InverseTechnology
52-Week High
$288.04$150.42
52-Week Low
$170.20$61.99
Market Cap
$2.54B
Enterprise Value
$2.94B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Direxion Daily S&P 500 Bull 3X Shares

SPXL is trading at $264.57, down 0.44% with a bearish technical signal. The ETF faces resistance at the 50-day moving average while support levels cluster around $262-$254. Recent news highlights S&P 500 valuation concerns with Shiller CAPE ratios approaching historic highs, creating headwinds for leveraged index products.

The leveraged ETF's performance remains tied to S&P 500 momentum amid mixed earnings sentiment. Key risks include market concentration in tech stocks and potential AI bubble concerns, while institutional analysis suggests the broader market may still deliver double-digit gains through 2026 despite valuation pressures.

TransMedics Group Inc

TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.

The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Direxion Daily S&P 500 Bull 3X Shares

SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.

Read more on SPXL

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX